Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
PRE 14A
Preliminary proxy
18 Apr 24
S-8
Registration of securities for employees
14 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
8-K
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
14 Mar 24
8-K
Vaxart, Inc. Appoints Steven Lo as New President, Chief Executive Officer, and Director
6 Mar 24
8-K
Departure of Directors or Certain Officers
29 Feb 24
8-K
Other Events
15 Feb 24
8-K/A
Departure of Directors or Certain Officers
2 Feb 24
8-K
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
19 Jan 24
424B5
Prospectus supplement for primary offering
17 Jan 24
8-K
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
16 Jan 24
8-K
Vaxart, Inc. Announces Management Change
16 Jan 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
2 Nov 23
8-K/A
Submission of Matters to a Vote of Security Holders
23 Oct 23
8-K
Amendments to Articles of Incorporation or Bylaws
23 Oct 23
8-K
Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate
6 Sep 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results
3 Aug 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
26 Jul 23
8-K
Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate
10 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
28 Jun 23
DEFA14A
Additional proxy soliciting materials
21 Jun 23
8-K
Vaxart, Inc. Announces Proposed Public Offering of Common Stock
8 Jun 23
424B5
Prospectus supplement for primary offering
8 Jun 23
424B5
Prospectus supplement for primary offering
6 Jun 23
8-K
No Vaccine Related Serious Adverse Events (SAEs) reported to date
6 Jun 23
8-K
Other Events
25 May 23
8-K
Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results
9 May 23
424B5
Prospectus supplement for primary offering
9 May 23
EFFECT
Notice of effectiveness
8 May 23
10-Q
2023 Q1
Quarterly report
4 May 23
CORRESP
Correspondence with SEC
3 May 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
31 Mar 23
UPLOAD
Letter from SEC
23 Mar 23
Latest ownership filings
4/A
Sean Tucker
1 Apr 24
4
Sean Tucker
1 Apr 24
4
James F. Cummings
1 Apr 24
4
Sean Tucker
20 Mar 24
4
Phillip E Lee
20 Mar 24
4
James F. Cummings
20 Mar 24
4
Edward B Berg
20 Mar 24
4
Steven Lo
20 Mar 24
3
Steven Lo
20 Mar 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G
RA CAPITAL MANAGEMENT, L.P.
19 Jan 24
4
W. Mark Watson
1 Aug 23
4
ELAINE J HERON
1 Aug 23
4
Robert A. Yedid
1 Aug 23
4
David E. Wheadon
1 Aug 23
4
Michael J. Finney
1 Aug 23
SC 13G/A
BlackRock Inc.
7 Jul 23
4
Phillip E Lee
14 Jun 23
4/A
Phillip E Lee
11 May 23
4
Cezar Andrei Floroiu
21 Mar 23
4
Edward B Berg
21 Mar 23
4
Phillip E Lee
21 Mar 23
4
Sean Tucker
21 Mar 23
4
James F. Cummings
21 Mar 23
SC 13G
VANGUARD GROUP INC
9 Feb 23
SC 13G/A
BlackRock Inc.
1 Feb 23
SC 13G/A
STATE STREET CORP
10 Jan 23
4
Phillip E Lee
30 Dec 22
3
Phillip E Lee
30 Dec 22
4
W. Mark Watson
28 Dec 22
4
Robert A. Yedid
7 Oct 22
4
Robert A. Yedid
26 Aug 22
4
ELAINE J HERON
25 Aug 22
3
ELAINE J HERON
25 Aug 22
4
Robert A. Yedid
22 Aug 22
4
W. Mark Watson
8 Aug 22
4
Robert A. Yedid
8 Aug 22
4
David E. Wheadon
8 Aug 22
4
Michael J. Finney
8 Aug 22
4
Todd C Davis
8 Aug 22